114.00
price down icon0.39%   -0.45
after-market Handel nachbörslich: 114.00
loading
Schlusskurs vom Vortag:
$114.45
Offen:
$114.47
24-Stunden-Volumen:
612.55K
Relative Volume:
0.51
Marktkapitalisierung:
$11.37B
Einnahmen:
$2.24B
Nettoeinkommen (Verlust:
$385.90M
KGV:
30.56
EPS:
3.73
Netto-Cashflow:
$440.10M
1W Leistung:
+3.57%
1M Leistung:
-2.99%
6M Leistung:
-0.92%
1J Leistung:
-17.29%
1-Tages-Spanne:
Value
$113.55
$115.80
1-Wochen-Bereich:
Value
$109.34
$116.23
52-Wochen-Spanne:
Value
$105.17
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Firmenname
Neurocrine Biosciences Inc
Name
Telefon
(858) 617-7600
Name
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Mitarbeiter
1,448
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
NBIX's Discussions on Twitter

Vergleichen Sie NBIX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
114.00 11.37B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.02 73.07B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.14 47.43B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.12 45.72B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.49 17.75B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.75 14.03B 612.78M -86.37M -62.91M -0.87

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Eingeleitet Deutsche Bank Hold
2024-10-10 Fortgesetzt Raymond James Outperform
2024-08-29 Hochstufung Piper Sandler Neutral → Overweight
2024-04-24 Hochstufung Wells Fargo Equal Weight → Overweight
2023-12-13 Fortgesetzt Citigroup Neutral
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-08-21 Bestätigt Mizuho Neutral
2023-07-24 Hochstufung SVB Securities Market Perform → Outperform
2023-07-06 Hochstufung BMO Capital Markets Underperform → Market Perform
2023-05-04 Hochstufung Guggenheim Neutral → Buy
2023-03-30 Hochstufung Canaccord Genuity Hold → Buy
2023-03-03 Hochstufung Evercore ISI In-line → Outperform
2023-02-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-11-14 Herabstufung Evercore ISI Outperform → In-line
2022-10-11 Eingeleitet UBS Buy
2022-09-26 Eingeleitet Wells Fargo Equal Weight
2022-06-06 Fortgesetzt Jefferies Buy
2022-03-03 Herabstufung Piper Sandler Overweight → Neutral
2022-02-25 Hochstufung Goldman Neutral → Buy
2022-01-18 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Eingeleitet BMO Capital Markets Underperform
2021-11-17 Hochstufung JP Morgan Neutral → Overweight
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-08-06 Herabstufung Canaccord Genuity Buy → Hold
2021-05-18 Fortgesetzt Goldman Neutral
2021-05-06 Hochstufung Barclays Equal Weight → Overweight
2021-02-02 Eingeleitet Raymond James Outperform
2020-09-30 Eingeleitet The Benchmark Company Hold
2020-08-04 Herabstufung JP Morgan Overweight → Neutral
2020-06-29 Herabstufung Goldman Buy → Neutral
2020-06-09 Eingeleitet Wedbush Outperform
2020-03-06 Eingeleitet Citigroup Buy
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-24 Eingeleitet William Blair Outperform
2020-02-06 Eingeleitet Mizuho Neutral
2020-02-05 Bestätigt H.C. Wainwright Buy
2019-12-13 Herabstufung Credit Suisse Outperform → Neutral
2019-08-07 Eingeleitet RBC Capital Mkts Outperform
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-05 Eingeleitet Guggenheim Neutral
2019-05-21 Eingeleitet Credit Suisse Outperform
2019-04-22 Hochstufung JP Morgan Neutral → Overweight
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-02-06 Bestätigt BofA/Merrill Buy
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-12-13 Eingeleitet Goldman Buy
2018-11-21 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten

pulisher
Mar 26, 2025

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tardive Dyskinesia Treatment Market Expands with New Drug - openPR

Mar 25, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - PR Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

Neurocrine at Stifel 2025 CNS Forum: Strategic Insights and Challenges - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Is Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules - PR Newswire

Mar 17, 2025
pulisher
Mar 15, 2025

Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN

Mar 15, 2025
pulisher
Mar 14, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Schizophrenia Treatment Market Size Report 2034 | Novartis - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

US Bancorp DE Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

RBC Capital cuts Neurocrine Bio. stock target to $139 from $148 - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Trend Tracker for (NBIX) - Stock Traders Daily

Mar 11, 2025
pulisher
Mar 11, 2025

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Neurocrine Leadership Reveals Next Steps in CNS Drug DevelopmentKey Presentation Coming - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Smartleaf Asset Management LLC Purchases 146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Tardive Dyskinesia Treatment Market Size, Share & Future - openPR

Mar 07, 2025
pulisher
Mar 06, 2025

Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions - Simply Wall St

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675 - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine begins phase 1 study of new neurological drug By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine begins phase 1 study of new neurological drug - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors - Simply Wall St

Mar 05, 2025
pulisher
Mar 05, 2025

Neurological Disorder Drugs Market Detailed In New Research - openPR

Mar 05, 2025
pulisher
Mar 04, 2025

Neurocrine Biosci stock hits 52-week low at $110.92 - Investing.com

Mar 04, 2025
pulisher
Mar 03, 2025

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week - MSN

Mar 03, 2025
pulisher
Mar 01, 2025

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.59 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Illumine Investment Management LLC Invests $1.30 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

GW&K Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Los Angeles Capital Management LLC Has $70 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Neurocrine Biosciences (NasdaqGS:NBIX) Highlights INGREZZA's Positive Phase 4 Study Results - Simply Wall St

Feb 28, 2025
pulisher
Feb 28, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Peloton Wealth Strategists - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Phase IV Ingrezza data move focus from sales outlook - The Pharma Letter

Feb 28, 2025
pulisher
Feb 28, 2025

NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Blackhawk Capital Partners LLC. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Feb 28, 2025

Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$8.84
price down icon 1.34%
$131.75
price up icon 0.05%
$97.04
price down icon 1.41%
$33.53
price down icon 0.47%
$10.81
price up icon 2.46%
Kapitalisierung:     |  Volumen (24h):